on October 19, 2006
Published online before print October 19, 2006, doi: 10.1161/01.ATV.0000250616.26308.d7
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 27, 2006
Accepted on September 28, 2006
Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk. Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST
Luis M. Blanco-Colio ;
From the Vascular Research Lab (L.M.B.-C., J.L.M.-V.), Fundación Jimenéz Díaz, Autonoma University, Madrid, Spain; University of Malaga & V. de la Victoria Hospital (E.d.T.), Malaga, Spain; 1st Department Med. Semmelweis University (C.F.), Budapest, Hungary; University of Glasgow (A.G.), Glasgow, UK; University of Florence, Careggi Hospital (G.G.), Firenze, Italy; University of Toronto & St-Michael’s Hospital (L.A.L., A.L.), Toronto, ON, Canada; Canadian Heart Research Centre (A.L.), Toronto, ON, Canada; Medical Division, Pfizer Canada (P.M.), Kirkland, QC, Canada; and R&D Department, Medical Division, Pfizer Spain (G.H.), Madrid, Spain.
* To whom correspondence should be addressed. E-mail: jegido{at}fjd.es.
Objectives--Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment.
Methods and Results--ACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk >20%. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides 
600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85% of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL.
Conclusions--sFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.
Key words: inflammation • atorvastatin • soluble Fas • C-reactive protein • statins
This article has been cited by other articles:
 |
|
 |
|
  G. A. Wellenius, K. J. Mukamal, A. Kulshreshtha, S. Asonganyi, and M. A. Mittleman Depressive Symptoms and the Risk of Atherosclerotic Progression Among Patients With Coronary Artery Bypass Grafts Circulation, May 6, 2008; 117(18): 2313 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Blanco-Colio, J. L. Martin-Ventura, B. Munoz-Garcia, J. Orbe, J. A. Paramo, J.-B. Michel, A. Ortiz, O. Meilhac, and J. Egido Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 916 - 922. [Abstract] [Full Text] [PDF]
|
|